Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H24N2O |
Molecular Weight | 380.4816 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=CC=C(OC3=CC=CC=C3)C=C2C4=C1CCN4CCC5=CC=CC=C5
InChI
InChIKey=XCZMUTGHJBFKPM-UHFFFAOYSA-N
InChI=1S/C26H24N2O/c1-19-23-15-17-28(16-14-20-8-4-2-5-9-20)26(23)24-18-22(12-13-25(24)27-19)29-21-10-6-3-7-11-21/h2-13,18H,14-17H2,1H3
Molecular Formula | C26H24N2O |
Molecular Weight | 380.4816 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:34 GMT 2023
by
admin
on
Sat Dec 16 11:36:34 GMT 2023
|
Record UNII |
ZE7QPY4258
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZE7QPY4258
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY | |||
|
16727326
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY | |||
|
936622-80-9
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Drug: HT 61(Primary), Chlorhexidine/neomycin, Mupirocin; Indication: Staphylococcal infections; Focus: Therapeutic Use; Sponsor: Helperby Therapeutics; Most Recent Events: 10 May 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record., 14 Mar 2012 New trial record
|
||
|
ACTIVE MOIETY |
Originator: Helperby Therapeutics; Class: Antibacterial, Quinolone, Small molecule; Mechanism of Action: Cell membrane modulator, Cell wall inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase III for Staphylococcal infections; Most Recent Events: 10 Jun 2015 Phase III development is ongoing in the United Kingdom, 04 Dec 2013 Phase-III development is ongoing in UK, 21 Feb 2012 Helperby Therapeutics initiates enrolment in a phase II trial for Staphylococcal infections in United Kingdom (EudraCT2011-002438-38)
|
||
|
ACTIVE MOIETY |
Results: Using the fractional inhibitory concentration index, no interaction was seen in both MSSA and MRSA for the pair HT61 and gentamicin or the pair HT61 and neomycin. Synergism was seen for 65% of both MSSA and MRSA when HT61 was combined with chlorhexidine. There was also no interaction between HT61 and mupirocin. Timekill analysis demonstrated significant synergistic activities when a low level of HT61 was combined with neomycin, gentamicin or chlorhexidine. The effect was more dramatic against non-multiplying bacteria against which the antimicrobials used were inactive on their own. Significant synergistic effects were also seen on mouse infected skin.
|